Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Smith & Nephew plc is a global medical technology company focused on the development, manufacture, and commercialization of products that support the repair, regeneration, and replacement of soft and hard tissue. The company operates primarily in the orthopaedics, sports medicine, wound care, and advanced surgical industries, serving hospitals, surgical centers, and healthcare professionals worldwide. Its core revenue drivers are implantable medical devices, surgical instruments, and advanced wound management solutions used in both elective and trauma-related procedures.
Founded in 1856 in the United Kingdom, Smith & Nephew began as a family-owned pharmacy business and gradually evolved into an international medical device manufacturer. Over more than a century, the company expanded through internal innovation and acquisitions, transitioning from traditional healthcare supplies to a technology-driven portfolio centered on orthopaedic reconstruction, arthroscopic surgery, and advanced wound care. Today, it is recognized for its scale, clinical focus, and long-standing relationships with healthcare providers.
Business Operations
Smith & Nephew organizes its operations into three primary business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The Orthopaedics segment includes joint replacement implants, trauma fixation devices, and robotic-assisted surgical systems, generating a significant portion of company revenue. Sports Medicine & ENT focuses on minimally invasive arthroscopic procedures, ligament repair, and related surgical technologies, while Advanced Wound Management provides products for chronic, acute, and surgical wound treatment.
The company operates manufacturing, research, and distribution facilities across multiple regions, with substantial operations in North America, Europe, and Asia-Pacific. Smith & Nephew controls a broad portfolio of proprietary technologies, including advanced biomaterials, robotics, and digital surgical planning systems. Its business model relies on direct sales forces in major markets, supplemented by distributors in smaller or emerging markets.
Strategic Position & Investments
Smith & Nephew’s strategic direction emphasizes higher-growth surgical segments, operational efficiency, and technology-led differentiation. The company has invested heavily in robotics, digital surgery, and biologics to strengthen its competitive position in orthopaedics and sports medicine. A notable strategic investment is the development and commercialization of the CORI Surgical System, designed to enhance precision and outcomes in joint replacement procedures.
The company has also pursued targeted acquisitions to expand capabilities and access new technologies. These include the acquisition of Osiris Therapeutics, which strengthened its biologics and regenerative medicine portfolio, and Integra LifeSciences’ extremity orthopaedics business, which expanded its presence in upper and lower extremity reconstruction. Smith & Nephew continues to evaluate opportunities in emerging surgical technologies and outpatient care settings.
Geographic Footprint
Smith & Nephew is headquartered in London, United Kingdom, and maintains a global operational footprint spanning North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The United States represents its single largest market, accounting for a substantial share of revenue, supported by extensive sales, manufacturing, and R&D operations.
Internationally, the company has a strong presence in key developed markets such as Germany, France, Japan, and Australia, while also expanding in faster-growing emerging markets, including China, India, and Brazil. This diversified geographic exposure allows Smith & Nephew to balance mature market stability with emerging market growth opportunities.
Leadership & Governance
Smith & Nephew is led by an executive team with deep experience in global medical technology, operations, and healthcare innovation. The leadership philosophy emphasizes clinical effectiveness, disciplined capital allocation, and sustainable growth through innovation and operational excellence. The company operates under a unitary board structure consistent with UK corporate governance standards.
Key executives include:
- Deepak Nath – Chief Executive Officer
- Anne-Françoise Nesmes – Chief Financial Officer
- Craig Turnbull – President, Global Orthopaedics
- Roland Diggelmann – President, Sports Medicine & ENT
- Alison Jones – Chief Human Resources Officer
The board and management team oversee strategy execution, risk management, and compliance with global regulatory requirements, with a focus on long-term value creation for shareholders and patients.